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Chlorofusin is a natural product that was first identified in a 
screen for inhibitors of the MDM2/p53 interaction.1, 2 It is a 
cyclic peptide in which one of the amino acids, an ornithine, is 
condensed with a densely functionalized azaphilone. Interest in 
both its biological activity, as an inhibitor of a protein-protein 
interaction, and its structure initiated a series of studies of the 
natural compound. The cyclic peptide was synthesized by both 
solid3 and solution phase4-6 methods, its stereochemistry and its 
lack of inherent biological activity were established. The total 
synthesis initially proved elusive as the first approach gave an 
erroneous structure to the azaphilone portion,7 although this was 
closely followed by the first total synthesis from the Boger 
laboratory.8,9 Interestingly, this approach allowed access to all the 
diastereomers of the azaphilone structure and showed that the 
presence of the azaphilone was required for MDM2/p53 
inhibition but the overall stereochemistry of the molecule had 
little effect.10 This has recently been confirmed through a further 
total synthesis.11 We have also shown that the introduction of 
substituents on the ornithine in order to generate simpler 
analogues does not lead to active MDM2/p53 inhibitors.12 Yao 
and co-workers have recently described a synthesis of 
chlorofusin analogues that incorporate a triazole moiety in the 
linker between the peptide and the azaphilone and these are the 
first chlorofusin analogues to show inhibitory activity in the 
MDM2/p53 assay.13 This has prompted us to disclose our own 
studies of a click chemistry-based approach to chlorofusin 
analogues that gave us the first simple non-azaphilone peptide 
analogues of chlorofusin with anti-MDM2 activity. However, on 
further probing, we found that the simple “clicked” amino acid 
that we incorporated into the chlorofusin peptide also had activity 
and was a relatively potent inhibitor of MDM2/p53 interactions. 
In order to facilitate these studies, we have also developed a 
fluorescence polarization based assay for screening purposes that 
is simpler than the previously described12 ELISA based assay. 
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Figure 1. Chlorofusin. 
 
Incorporation of an azide moiety into our solid phase protocol 
would give us a compound that could undergo click chemistry14 
either while still on the resin or following cleavage. For this, we 
required an Fmoc protected azide-containing amino acid. We 
utilized a route from Boc-glutamic acid α-t-butyl ester 1 to 
generate an azide analogue of ornithine in a modest yield, but 
through a scalable process (Scheme 1). Boc-glutamic acid α-t-
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butyl ester 1 was treated with carbonyldiimidazole and then 
reduced to alcohol 2 with sodium borohydride in a one pot, two 
step procedure, producing the expected compound in excellent 
yield. Mesylation and subsequent treatment of the crude with 
sodium azide15 generated the required side chain on the amino 
acid (4). The product does not require purification and was 
treated with a saturated solution of hydrochloric acid in ethyl 
acetate at room temperature to remove both the Boc and tBu 
protecting groups. Evaporation of the solvent and reaction of the 
residue with Fmoc-Cl in the presence of sodium carbonate gave 
the target amino acid 5. 
 
Scheme 1. Synthesis of the azide analogue of ornithine. 
 
Incorporation of 5 in to the solid phase synthesis3 proceeded 
smoothly (Scheme 2) and the azide was formed on resin, as 
demonstrated by cleavage of a small sample and analysis by mass 
spectrometry. A convenient route to derivatising this compound 
would be to carry it out on resin, provided the triazole-forming 
reaction proceeded under these conditions. We had previously 
found that acylation of the ornithine on resin was a convenient 
approach to generate analogues.12 To our satisfaction, treatment 
of the resin bound peptide (6) with a selection of alkynes with 
different functional groups led to the successful generation of 
click analogues. These could be removed from the resin using a 
standard cleavage cocktail (95% TFA, 2.5 % H2O, 2.5% TIPS) 
and purified by preparative HPLC.  
The compounds were screened by a convenient fluorescence 
polarization (FP) assay, adapted from several that have been 
previously published.16 The high affinity peptide 
LTFEHYWAQLTS was synthesised on Rink amide resin to 
generate the amide at the C-terminus and was tagged with FAM 
at the N-terminus. Human MDM2 protein (17-125) was used in 
the polarization assay and the wildtype p53 peptide (residues 15-
27) was used as a positive control and had an IC50 of 14.45 µM 
and Ki of 9.19 µM. Screening the click chlorofusin analogues 7-
16 at 100 µM concentration revealed that only the 4-
methylphenyl (8) inhibited the MDM2/peptide interaction. A full 
inhibition curve for compound 8 revealed the methylphenyl 
compound had an IC50 of 66.01 µM and Ki of 8.309 µM. This is 
the first time that simple analogues of chlorofusin have been 
shown to have activity against MDM2 and compound 8 has a 
similar affinity to the wildtype p53 peptide.  
 
Scheme 2. Solid phase synthesis of analogues of chlorofusin peptide.  
 
It seemed reasonable to explore the binding of the ornithine 
amino acid analogue to confirm that the peptide structure of 
chlorofusin was contributing to the binding of the click chemistry 
product. The 4-(4-methylphenyl)triazole structure is significantly 
different from the azaphilone of the natural product and it was a 
possibility that the side chain itself was responsible for the 
biological activity. With this in mind, the ornithine azide with 
Fmoc-protection 5 was treated with 4-ethynyltoluene and, as a 
further novel analogue, 4-trifluoromethylphenylethylene under 
the conditions of the click chemistry reaction (Scheme 3). The 
yields were excellent and the products could be isolated without 
chromatographic purification. Nonetheless, to ensure ideal purity, 
they were additionally subjected to preparative HPLC.   When 
these compounds were tested in the FP assay, we were surprised 
to discover that they also inhibited the MDM2/p53 interaction, 
with the 4-methylphenyl compound having improved activity in 
comparison with the full peptide structure (Table 1). 
The presence of halides is often seen as preferential for MDM2 
binding ligands and so we also generated a number of analogues 
containing the Cl, Br and I phenyl systems. In order to probe the 
potential size of the binding site, we made a methoxy analogue as 
the methylphenyl- compound was more active than the 
trifluoromethylphenyl. When screened in the FP assay, all of 
these compounds except for the chlorophenyl- compound were 
inhibitors of the p53 peptide/MDM2 interaction. The most potent 
compound with the highest binding affinity was the iodo- 
derivative although the binding affinity of the bromo compound 
was very similar. Binding of the 4-methoxy compound was also 
enhanced compared with the methyl, suggesting that the larger 
group is filling a binding pocket on the MDM2 protein more 
efficiently than the smaller CH3. All of these compounds 
compare well with the p53 peptide, with higher affinity. When 
the well-known anti-MDM2 compound nutlin 3a was compared 
in the same assay, its IC50 value was about 5 fold lower than that 
of the iodo compound, suggesting that it is maintaining a slightly 
higher potency than these new compounds in this assay. 
 
Scheme 3. Synthesis of compounds 19-26 
 
Compounds IC50 (µM)a             Ki (µM)b 
17 24.26                    3.05 
18 49.80                    6.96 
20 5.51                      0.69 
21 
22 
23 
Nutlin 3A 
2.90                      0.36 
5.66                      0.71 
57.36                    7.22 
0.61 
aConcentration of substrate required to decrease polarization 
fluorescence by 50%.bApparent inhibition constant. 
    Removal of the Fmoc group from the compound 18 to generate 
24 leads to a complete loss of activity, suggesting that a 
hydrophobic group is required in this position of the molecule. 
Screening of the t-Bu ester version of the iodo compound, which 
we suspected would lead to cellular uptake of these compounds, 
also led to loss of activity for binding. 
A preliminary screen in a proliferation assay was also 
undertaken. Compounds 19-23 showed no activity against either 
SJSA-1 (osteosarcoma, amplification of MDM2) or A375 cell 
lines (melanoma, wild type p53, normal MDM2). However, both 
compounds 17 and 18 showed some activity, with 17 being 
active in the SJSA-1 cell line (33.1 µM) and inactive in A375 
whereas 18 was active in both cell lines (31.2 µM, 49.3 µM). 
Cell-based assays such as these are not direct indicators of 
whether the compounds are acting through the inhibition of 
MDM2/p53 and the fact that 18 is active in both cell lines is 
indicative of a different mechanism or mechanisms of action. 
Cell based assays that offer a more definitive demonstration of 
intracellular activity have recently been described17 and we will 
explore the utility of these approaches. 
 In conclusion, we have developed new analogues of 
chlorofusin via click chemistry that have the ability to prevent the 
binding of the p53 peptide to the MDM2 protein. Chlorofusin 
could be considered to be the product of a natural “fragment-
based” approach to small molecule development – with the 
condensation of an azaphilone and a cyclic peptide leading to an 
active molecule. In a similar vein, we have used the cyclic 
peptide as a template to generate new molecules to bind to 
MDM2. Further investigation of those molecules has led to the 
identification of a new small molecule motif, based around the 
click product of an Fmoc-protected ornithine, which can also 
inhibit the p53/MDM2 interaction. It would be interesting to see 
if the azaphilone click analogues recently described12 also have 
activity as the Fmoc-amino acid structure.  Studies are continuing 
to identify the binding site and the structure-activity relationship 
for this new class of compound. 
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